 |
|
Discoveries may advance stem cell therapy for Parkinson's, cancer patients
January 27, 2006Two studies in the Jan. 27, 2006 Cell have yielded evidence that could prove a boon for stem cell therapies aimed at patients with Parkinson's disease and those with compromised immune systems due to intensive cancer therapy or autoimmune disease, according to researchers. The basic findings in mice revealed critical factors that determine the fate of one type of nerve cell progenitor and that set bone marrow stem cells into action.
Researchers at the Karolinska Institutet in Sweden discovered a "master determinant" that turns embryonic stem cells into bona fide dopamine neurons, brain cells that degenerate in those with Parkinson's disease. The findings hold promise for the future of cell replacement therapy for the debilitating and incurable disease characterized by tremors, said study authors Thomas Perlmann and Johan Ericson. The results also underscore the general importance of a thorough understanding of development for producing authentic cells of a desired type from stem cells.
"The use of cell replacement therapy in the treatment of Parkinson's disease is fraught with many problems," Perlmann said. "However, clinical trials have provided important proof of principle that transplantation of dopamine neurons might work in patients."
"Ethical and practical issues associated with transplantation of fetal dopamine neurons to patients with Parkinson's disease has triggered intense interest in the possibility of the use of in vitro-engineered stem cells as an unlimited cellular source for transplantation," the researchers added.
To investigate whether the identification of determinants underlying the specification of dopamine neurons during development could be exploited for generating dopamine neurons from stem cells, the researchers first looked for genes expressed in the dopamine progenitor cells in the developing midbrains of embryonic mice.
The researchers uncovered two transcription factor proteins, Lmx1a and Msx1, that are selectively expressed in dopamine progenitor cells. Further study found that Lmx1, but not Msx1, is sufficient and required for the formation of dopamine neurons in the midbrains of chicks. Early activity of Lmx1a induces expression of Msx1, leading to other events important to the differentiation of these nerve cells, they show.
Moreover, the researchers report that expression of Lmx1a in embryonic stem cells results in a robust generation of dopamine neurons with a correct midbrain identity.
"We spent a lot of effort and are now confident that these are authentic dopamine neurons," Ericson said. "If we want to treat Parkinson's patients with stem cells, it will only work if we are able to generate authentic dopamine cells."
"In the use of stem cells for therapy, it is of utmost importance to make the correct cell type," added Perlmann. "In the brain, there are at least 1000 different types of neurons, only one of which is clinically relevant to Parkinson's disease-a fact which emphasizes the complexity of the problem. Our data establish Lmx1a and Msx1 as critical intrinsic dopamine-neuron determinants in vivo and suggest that they may be essential tools in cell replacement strategies in Parkinson's disease."
Further study will elucidate the utility of the stem cell-derived neurons for treating rats with Parkinson's disease, they said. The researchers will also conduct studies to examine whether the findings in animals will hold for humans.
A second group at Mount Sinai School of Medicine in New York found that the sympathetic-or "fight or flight" branch-of the nervous system plays a critical role in coaxing bone marrow stem cells into the bloodstream. So-called hematopoietic stem cells in the bone marrow are the source for blood and immune cells.
Hematopoietic stem cell transplants are now routinely used to restore the immune systems of patients after intensive cancer therapy and for treatment of other disorders of the blood and immune system, according to the National Institutes of Health. While physicians once retrieved the stem cells directly from bone marrow, doctors now prefer to harvest donor cells that have been mobilized into circulating blood.
In normal individuals, the continuous trafficking of the stem cells between the bone marrow and blood fills empty or damaged niches and contributes to the maintenance of normal blood cell formation, according to the researchers. Although it has been known for many years that the mobilization of hematopoietic stem cells can be enhanced by multiple chemicals, the mechanisms that regulate this critical process are largely unknown, they said.
One factor in particular, known as hematopoietic cytokine granulocyte-colony stimulating factor (G-CSF), is widely used clinically to elicit hematopoietic stem cell mobilization for life-saving bone marrow transplantation, said senior author of the study, Paul Frenette.
Several years ago, Frenette's group reported that a second compound, fucoidan, which is synthesized by certain seaweeds, could also spur the stem cells into action. The group speculated that the seaweed derivative might work by imitating a similar compound, called sulfatide, naturally present in mammalian tissues.
To test the idea, the researchers examined mice lacking the enzyme responsible for making sulfatide.
"Lo and behold, mice lacking the enzyme Cgt did not mobilize hematopoietic stem cells at all when treated with the stimulating factor G-CSF or fucoidan," Frenette said. "You don't get such dramatic results that often in science. We knew we had stumbled onto something important."
To their surprise, further study failed to connect the stalled stem cell movement to sulfatide. Rather, they found, the deficiency stemmed from a defect in the transmission of signals sent via the sympathetic nervous system. The products of Cgt contribute to the myelin sheath that coats and protects nerve cells, they explained.
Mice with other nervous system defects also exhibited a failure to mobilize bone marrow stem cells, they found. Moreover, drugs that stimulate the sympathetic nervous system restored stem cell movement into the blood stream in mice with an impaired ability to respond to norepinephrine, the signature chemical messenger of the sympathetic system.
"The nervous system plays an important role in producing signals that maintain the stem cell niche and retention in bone marrow," Frenette said.
"The new findings add another dimension of complexity to the processes involved in stem cell maintenance and mobilization and emphasize the interrelationships among the nervous, skeletal and hematopoietic systems," he added. "They all have to work together - to talk to each other - to produce blood and maintain stem cells."
The results suggest that differences in the sympathetic nervous systems of stem cell donors may explain "conspicuous variability" in the efficiency with which they mobilize hematopoietic cells into the bloodstream, the researchers said. Furthermore, drugs that alter the signals transmitted by the sympathetic nervous system to the stem cells in bone may offer a novel strategy to improve stem cell harvests for stem cell-based therapeutics, they added.
"The new findings suggest that the nervous system, which has the inherent ability to integrate information from throughout the organism, may govern the local relationship between stem cells and their niches," said Jonas Larsson and David Scadden of the Harvard Stem Cell Institute in a preview.
The unexpected findings by Frenette and his colleagues further "suggest that the pharmacological manipulation of the sympathetic nervous system may be a means of therapeutically targeting the stem cells in their niche for the purpose of either mobilization or, conversely, attracting stem cells to the niche following transplantation," they added.
Cell Press
"Ethical and practical issues associated with transplantation of fetal dopamine neurons to patients with Parkinson's disease has triggered intense interest in the possibility of the use of in vitro-engineered stem cells as an unlimited cellular source for transplantation," the researchers added.
To investigate whether the identification of determinants underlying the specification of dopamine neurons during development could be exploited for generating dopamine neurons from stem cells, the researchers first looked for genes expressed in the dopamine progenitor cells in the developing midbrains of embryonic mice.
The researchers uncovered two transcription factor proteins, Lmx1a and Msx1, that are selectively expressed in dopamine progenitor cells. Further study found that Lmx1, but not Msx1, is sufficient and required for the formation of dopamine neurons in the midbrains of chicks. Early activity of Lmx1a induces expression of Msx1, leading to other events important to the differentiation of these nerve cells, they show.
Moreover, the researchers report that expression of Lmx1a in embryonic stem cells results in a robust generation of dopamine neurons with a correct midbrain identity.
"We spent a lot of effort and are now confident that these are authentic dopamine neurons," Ericson said. "If we want to treat Parkinson's patients with stem cells, it will only work if we are able to generate authentic dopamine cells."
"In the use of stem cells for therapy, it is of utmost importance to make the correct cell type," added Perlmann. "In the brain, there are at least 1000 different types of neurons, only one of which is clinically relevant to Parkinson's disease-a fact which emphasizes the complexity of the problem. Our data establish Lmx1a and Msx1 as critical intrinsic dopamine-neuron determinants in vivo and suggest that they may be essential tools in cell replacement strategies in Parkinson's disease."
Further study will elucidate the utility of the stem cell-derived neurons for treating rats with Parkinson's disease, they said. The researchers will also conduct studies to examine whether the findings in animals will hold for humans.
A second group at Mount Sinai School of Medicine in New York found that the sympathetic-or "fight or flight" branch-of the nervous system plays a critical role in coaxing bone marrow stem cells into the bloodstream. So-called hematopoietic stem cells in the bone marrow are the source for blood and immune cells.
Hematopoietic stem cell transplants are now routinely used to restore the immune systems of patients after intensive cancer therapy and for treatment of other disorders of the blood and immune system, according to the National Institutes of Health. While physicians once retrieved the stem cells directly from bone marrow, doctors now prefer to harvest donor cells that have been mobilized into circulating blood.
In normal individuals, the continuous trafficking of the stem cells between the bone marrow and blood fills empty or damaged niches and contributes to the maintenance of normal blood cell formation, according to the researchers. Although it has been known for many years that the mobilization of hematopoietic stem cells can be enhanced by multiple chemicals, the mechanisms that regulate this critical process are largely unknown, they said.
One factor in particular, known as hematopoietic cytokine granulocyte-colony stimulating factor (G-CSF), is widely used clinically to elicit hematopoietic stem cell mobilization for life-saving bone marrow transplantation, said senior author of the study, Paul Frenette.
Several years ago, Frenette's group reported that a second compound, fucoidan, which is synthesized by certain seaweeds, could also spur the stem cells into action. The group speculated that the seaweed derivative might work by imitating a similar compound, called sulfatide, naturally present in mammalian tissues.
To test the idea, the researchers examined mice lacking the enzyme responsible for making sulfatide.
"Lo and behold, mice lacking the enzyme Cgt did not mobilize hematopoietic stem cells at all when treated with the stimulating factor G-CSF or fucoidan," Frenette said. "You don't get such dramatic results that often in science. We knew we had stumbled onto something important."
To their surprise, further study failed to connect the stalled stem cell movement to sulfatide. Rather, they found, the deficiency stemmed from a defect in the transmission of signals sent via the sympathetic nervous system. The products of Cgt contribute to the myelin sheath that coats and protects nerve cells, they explained.
Mice with other nervous system defects also exhibited a failure to mobilize bone marrow stem cells, they found. Moreover, drugs that stimulate the sympathetic nervous system restored stem cell movement into the blood stream in mice with an impaired ability to respond to norepinephrine, the signature chemical messenger of the sympathetic system.
"The nervous system plays an important role in producing signals that maintain the stem cell niche and retention in bone marrow," Frenette said.
"The new findings add another dimension of complexity to the processes involved in stem cell maintenance and mobilization and emphasize the interrelationships among the nervous, skeletal and hematopoietic systems," he added. "They all have to work together - to talk to each other - to produce blood and maintain stem cells."
The results suggest that differences in the sympathetic nervous systems of stem cell donors may explain "conspicuous variability" in the efficiency with which they mobilize hematopoietic cells into the bloodstream, the researchers said. Furthermore, drugs that alter the signals transmitted by the sympathetic nervous system to the stem cells in bone may offer a novel strategy to improve stem cell harvests for stem cell-based therapeutics, they added.
"The new findings suggest that the nervous system, which has the inherent ability to integrate information from throughout the organism, may govern the local relationship between stem cells and their niches," said Jonas Larsson and David Scadden of the Harvard Stem Cell Institute in a preview.
The unexpected findings by Frenette and his colleagues further "suggest that the pharmacological manipulation of the sympathetic nervous system may be a means of therapeutically targeting the stem cells in their niche for the purpose of either mobilization or, conversely, attracting stem cells to the niche following transplantation," they added.
Cell Press
Stem Cell Therapy News and Current Stem Cell Therapy Events RSSAdult stem cells activated in mammalian brain
Adult stem cells originate in a different part of the brain than is commonly believed, and with proper stimulation they can produce new brain cells to replace those lost to disease or injury, a study by UC Irvine scientists has shown.
Novel hydrogel systems for dentin regeneration
Dental caries, or tooth decay, continues to be the most prevalent infectious disease in the world, presenting significant public health challenges and socio-economic consequences.
Adult stem cells may be beneficial for certain cardiovascular disorders and autoimmune diseases
A review of previously published research suggests that stem cells harvested from an adult's blood or marrow may provide treatment benefit to select patients for some autoimmune diseases and cardiovascular disorders.
Targeting astrocytes slows disease progression in ALS
In what the researchers say could be promising news in the quest to find a therapy to slow the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, scientists at the University of California, San Diego (UCSD) School of Medicine have shown that targeting neuronal support cells called astrocytes sharply slows disease progression in mice.
Stem cell research aims to tackle Parkinson's disease
Scientists in Sweden are developing new ways to grow brain cells in the laboratory that could one day be used to treat patients with Parkinson's disease, an international conference of biologists organised by the European Science Foundation (ESF) was told last week.
USC researchers identify mechanism that controls activation of stem cells during hair regeneration
Researchers at the University of Southern California (USC) have identified a novel cyclic signaling in the dermis that coordinates stem cell activity and regulates regeneration in large populations of hairs in animal models.
PET and Bioluminescent Imaging Aid Evaluation of Stem Cells' Potential for New Ways to Treat Disease
Using positron emission tomography (PET) imaging with bioluminescence-the light produced by a chemical reaction within an organism-researchers are starting to understand the behavior of transplanted or implanted stem cells that may one day be used to develop new treatments for disease.
Menstruation proves more than a curse
The cells which thicken the womb wall during a woman's menstrual cycle contain a newly discovered type of stem cell, and could be used in the treatment of damaged and/or old tissue.
U of M performs first systemic therapy for fatal childhood disease
University of Minnesota Children's Hospital, Fairview physicians have performed the first bone marrow and cord blood transplant to treat recessive dystrophic epidermolysis bullosa (RDEB).
Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
Heart disease is the leading cause of death in the United States and greatly affects the quality and length of life for individuals with specific forms of muscular dystrophy.
More Stem Cell Therapy News Articles
 | The Oxygen Revolution: Hyperbaric Oxygen Therapy: The Groundbreaking New Treatment for Stroke, Alzheimer's, Parkinson's, Arthritis, Autism, Learning Disabilities and More by Paul G. Harch, Virginia Mccullough HOPE FOR MANY "HOPELESS" DISEASES, FROM ONE OF THE FOREMOST RESEARCHERS IN THE FIELDWhen Randy McCloy, Jr., the sole survivor of the Sago Mine disaster, finally walked out of the hospital to rejoin his family, it was in part due to the miracle of hyperbaric oxygen therapy. Hyperbaric oxygen therapy (HBOT) is based on an almost laughably simple idea: Oxygen can be used therapeutically for a wide... |
 | Umbilical Cord Stem Cell Therapy: The Gift of Healing from Healthy Newborns by David A. Steenblock, Anthony G., Ph.D. Payne We are standing at the threshold of a new and exciting medical era-an era of regeneration, rejuvenation, and renewal in which stems cells will set the stage for healing and in some cases, the restoration of injured, diseased, and debilitated tissues and organ. While stem cell therapy is still in its infancy, the field is rich with promise. The debate over the use of embryonic stem cells and... |
 | Healing the Brain by Curt Freed, Simon LeVay Convinced that drug therapies based on dopamine replacement would never fully relieve the symptoms of Parkinson's disease, Dr. Curt Freed instead cut to the core of the matter--quite literally--and explored ways to replace damaged neurological systems caused by the disease. Healing the Brain meticulously chronicles his development and testing of a controversial surgical method, in which... |
 | How Adult Stem Cell Therapies Saved My Life: Medicine's Best-Kept Secret Can Save Your Life, Too by Bernard Van Zyl Laced with hope and promise, How Adult Stem Cell Therapies Saved My Life: Medicine's Best-Kept Secret Can Save Your Life, Too is the story of one man's quest to survive congestive heart failure and tout the nearly miraculous results of adult stem cell treatments. Seven years ago, van Zyl suffered cardiac arrest; his heart literally stopped until doctors shocked his chest. Over the next ten... |
 | Marrow Protection: Transduction of Hematopoietic Cells with Drug Resistance Genes by J. R., Ed. Bertino |
 | Cancer Stem Cells: Novel Concepts and Prospects for Tumor Therapy (Ernst Schering Foundation Symposium Proceedings) Cancer stem cells werehave originally been identified in leukemia and later in several solid tumor types. They have very different properties from the bulk of the tumor, as they divide much more slowly and have very efficient drug- resistance mechanisms. Current treatments might largely spare cancer stem cells, thus leading to tumor recurrence and metastasis. The recent identification of growth... |
 | Stem Cell Symphony: A Novel by Ricki Lewis Stuart Matheson, 32, is trapped in a nursing home as well as his body, eerily immobile at the last stage of Huntington's Disease. Kelsey Raye is a science writer feeling guilty about the recent deaths of her parents. She volunteers for hospice and is assigned to Stuart. She's a PhD, he never finished school, but they share a love of rock music... |
 | Stem Cell and Gene-Based Therapy: Frontiers in Regenerative Medicine The inability of the human body to be able significantly to self repair injured organs and tissues results in a considerable medical and social problem. During the last few years there has been incredible progress, and the achievements in experimental strategies for tissue regeneration, particularly in cell transplantation and stem cell research, have led to potential treatment options for many... |
 | Cardiovascular Regeneration and Stem Cell Therapy by Annarosa, MD Leri, Piero, MD Anversa, William H., MD Frishman This book is the definitive reference on two of the most exciting areas of cardiovascular research – myocardial regeneration and stem cell therapy – for the treatment of disease. Edited by pioneers in the area, with contributions from every major investigator worldwide, it covers:The biology of stem cells The actions of stem cells from the bone marrow, the heart, and embryos on the... |
 | Becoming Immortal: Combining Cloning and Stem-Cell Therapy by Stanley Shostak Explores how new organs might be engineered via cloning and reproductive technology to produce human... |
| © 2008 BrightSurf.com |